Necrosis avid contrast agents: Functional similarity versus structural diversity

Investigative Radiology

Volumn 40, Issue 8, 2005, Pages 526-535

  Ni, Yicheng ^a   Bormans, Guy ^b   Chen, Feng ^a,c   Verbruggen, Alfons ^b   Marchal, Guy ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

Animal experiment; Cardiac; Contrast agent; Infarction; Mechanism; MRI; Necrosis

Indexed keywords

ALBUMIN; BISGADOLINIUM PENTETATE BISINDOLE DERIVATIVE; BISGADOLINIUM PENTETATE PAMOIC ACID DERIVATIVE; CONTRAST MEDIUM; ECIII 60; ECIV 7; EMBONIC ACID; EVANS BLUE; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE DERIVATIVE; GADOPHERIN 2; GADOPHERIN 3; HEMATOPORPHYRIN; HYPERICIN; MANGAFODIPIR; MANGANESE; MANGANESE TETRAPHENYLPORPHYRIN; MP 2269; NECROSIS AVID CONTRAST AGENT; PORPHYRIN DERIVATIVE; SACCHARIC ACID; TETRAPHENYLPORPHYRIN DERIVATIVE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADRENAL GLAND; ANIMAL EXPERIMENT; BLOOD; BLOOD POOL CONTRAST EFFECT; CHEMICAL LABELING; CONTRAST ENHANCEMENT; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; FIRST PASS EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEPATOBILIARY SYSTEM; KIDNEY FUNCTION; MONITORING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOTOXICITY; PHYSICAL CHEMISTRY; PIGMENT DISORDER; PRIORITY JOURNAL; REVIEW; SPLEEN; STRUCTURE ACTIVITY RELATION; TISSUE NECROSIS; TREATMENT OUTCOME;

EID: 22844434974     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000171811.48991.5a     Document Type: Review

References (98)

1. Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation. 1998;98:2687-2694.
2. Kim FJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.
3. Pereira RS, Prato FS, Wisenberg G, et al. The use of Gd-DTPA as a marker of myocardial viability in reperfused acute myocardial infarction. Int J Cardiovasc Imaging. 2001;17:395-404.
4. Weinmann HJ, Ebert W, Misselwitz B, et al. Tissue-specific MR contrast agents. Eur J Radiol. 2003;46:33-44.
5. Oshinski JN, Yang Z, Jones JR, et al. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation. 2001; 104:2838-2842.
6. Saeed M, Lund G, Wendland MF, et al. Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation. 2001;103:871-876.
7. Choi CJ, Haji-Momenian S, Dimaria J, et al. Contrast washout by MRI identifies stunned myocardium in patients after reperfused myocardial infarction [abstract]. J Cardiovasc Mag Res. 2002;4:19.
8. Ni Y, Pislaru C, Bosmans H, et al. Intracoronary delivery of Gd-DTPA and gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol. 2001;11:876-883.
9. Judd RM, Kim RJ. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging (with response). Circulation. 2002;106:e6.
10. Flotats A, Carrió I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging. 2003;30:615-630.
11. Adzamli IK, Blau M, Pfeffer MA, et al. Phosphonate-modified Gd-DTPA complexes. III: the detection of myocardial infarction by MRI. Magn Reson Med. 1993;29:505-511.
12. 2+) pyrophosphate in ischemic and infarcted dog myocardium in early stages of acute coronary occlusion: histochemical and tissue-counting comparisons. J Nucl Med. 1983;24:485-491.
13. Khaw BA, Strauss HW, Moore R, et al. Myocardial damage delineated by indium-III antimyosin Fab and technetium-99m pyrophosphate. J Nucl Med. 1987;28:76-82.
14. Weissleder R, Lee A, Khaw B, et al. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology. 1992;182:381-385.
15. Roberts RM. Serendipity: Accidental Discoveries in Science. New York: John Wiley & Sons, Inc. 1989.
16. Kessel D. Porphyrin localization: a new modality for detection and therapy of tumors. Biochem Pharmacol. 1984;33:1389-1393.
17. Gomer C. Photodynamic therapy in the treatment of malignancies. Semin Hematol. 1989;26:27-34.
18. Nelson J, Schmiedl U, Shankland E. Metalloporphyrins as tumor-seeking MRI contrast media and as potential selective treatment sensitizers. Invest Radiol. 1990;25:571-73.
19. Pass H. Photodynamic therapy in oncology: mechanisms and clinical use (review). J Natl Cancer Inst. 1993;85:443-456.
20. Chen C, Cohen J, Myers C, Sohn M. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett. 1984;168:70-74.
21. Ogan M, Revel D, Brasch R. Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging. A study of human carcinoma, lymphoma, and fibrosarcoma in mice. Invest Radiol. 1987;22: 822-828.
22. Furmanski P, Longley C. Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. Cancer Res. 1988;48:4604-4610.
23. Van Zijl PCM, Place DA, Cohen JS, et al. Metalloporphyrin magnetic resonance contrast agents: feasibility of tumor-specific magnetic resonance imaging. Acta Radiol Suppl (Stockh). 1990;374:75-79.
24. Fiel RJ, Musser DA, Mark EH, et al. A comparative study of manganese meso-sulphonatophenyl porphyrins: contrast enhancing agents for tumors. Magn Reson Imaging. 1990;8:255-259.
25. Bockhorst K, Hohn-Berlage M, Kocher M, et al. Proton relaxation enhancement in experimental brain tumors: in vivo NMR study of manganese (III) TPPS in rat brain gliomas. Magn Reson Imaging. 1990;8:499-504.
26. Nelson J, Schmiedl U. Porphyrins as contrast media. Magn Reson Med. 1991;22:366-71.
27. Place DA, Faustino JP, Berghmans KK, et al. MRI contrast-dose relationship of manganese (III) tetra (4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T. Magn Reson Imaging. 1992;10:919-928.
28. Ebert E, Hofmann S, Swiderski U Metallopophyrins: tumor-specific contrast agents? In: Rinck PA, Muller RN, editors. New Developments in Contrast Agent Research. Hamburg, Germany: European Magnetic Resonance Forum Foundation; 1992:127-40.
29. Hindré F, LePlouzennec M, de Certained JD, et al. Tetra-p-amonophenylporphyrin conjugated with Gd-DTPA: tumor-specific contrast agent for MR imaging. JMRI. 1993;3:59-65.
30. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of Gadolinium (III) texaphyrin complex: A new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol. 1994;29:330-338.
31. Saini SK, Jena A, Dey J, et al. MnPcS4: A new MRI contrast enhancing agent for tumor localization in mice. Magn Reson Imaging. 1995;13: 985-990.
32. Ni Y, Marchal G, Herijgers P, et al. Paramagnetic metalloporphyrins: from enhancers for malignant tumors to markers of myocardial infarcts. Acad Radiol. 1996;3:S395-S397.
33. Ni Y, Marchal G, Van Damme B, et al. L. Magnetic resonance imaging, microangiography and histology in a rat model of primary liver cancer. Invest Radiol. 1992;27:689-697.
34. Ni Y, Marchal G, Yu J, et al. Localization of metalloporphyrin induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic and histologic findings. Acad Radiol. 1995;2:687-699.
35. Ni Y, Petré C, Miao Y, et al. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol. 1997;32:770-779.
36. Ni Y, Miao Y, Semmler W, et al. Manganese-metalloporphyrin (ATN-10) as a tumor-localizing agent: magnetic resonance imaging and inductively coupled plasma atomic emission spectroscopy study with experimental brain tumors [letter to the editor]. Neurosurgery. 1999;44:1146-1149.
37. Nasu H, Takehara Y, Isogai S, et al. Tumor enhancement using Mn-metalloporphyrin in mice: magnetic resonance imaging and histopathologic correlation. J Magn Reson Imaging. 2004;20:294-299.
38. Ni Y. Myocardial viability. In: Bogaert J, Ducrinckx AL, Rademakers FE, eds. Magnetic Resonance of the Heart and Great Vessels: Clinical Applications. 1st ed. Berlin: Springer; 1998:113-132.
39. Pislaru S, Ni Y, Pislaru C, et al. Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation. 1999;99:690-696.
40. Dymarkowski S, Ni Y, Miao Y, et al. Value of T2-weighted MRI early after myocardial infarction in dogs: comparison with bis-gadolinium-mesoporphyrin enhanced T1-weighted MRI and functional data from cine MRI. Invest Radiol. 2002;37:77-85.
41. Ni Y, Cresens E, Adriaens P, et al. Necrosis avid contrast agents: introducing nonporphyrin species. Acad Radiol. 2002;9(suppl 1):S98-S101.
42. Ni Y, Cresens E, Adriaens P, et al. Exploring multifunctional features of necrosis avid contrast agents. Acad Radiol. 2002;9(suppl 2):S488-S490.
43. Ni Y, Dymarkowski S, Chen F, et al. Occlusive myocardial infarction: enhanced or not enhanced with necrosis avid contrast agents at magnetic resonance imaging. Radiology. 2002;225:603-605.
44. Ni Y, Marchal G, Petré C, et al. Metalloporphyrin enhanced magnetic resonance imaging of acute myocardial infarction [abstract]. Circulation. 1994;90(Suppl):1-468.
45. Marchal G, Ni Y, Herijgers P, et al. Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by magnetic resonance imaging. Eur Radiol. 1996;6:1-8.
46. Herijgers P, Laycock SK, Ni Y, et al. Localization and determination of infarct size by Gd-mesoporphyrin enhanced MRI in dogs. Int J Cardiac Imaging. 1997;13:499-507.
47. Marchal G, Ni Y. U.S. patent No. 6,013,241: Use of porphyrin-complex or expanded porphyrin-complex as an infarction localization diagnosticum. Priority date: May 11, 1994; Date of Patent: January 11, 2000.
48. Ni Y, Pislaru C, Bosmans H, et al. Validation of intracoronary delivery of metalloporphyrin as an in vivo "histochemical staining" for myocardial infarction with MR imaging. Acad Radiol. 1998;5(Suppl 1):S37-S41.
49. Schneider G, Hayd C, Müller A, et al. Contrast enhanced MRI of experimentally induced brain infarctions in rabbits using Bis-Gd-MP as MR contrast agent. Proceedings of the Third Annual Scientific Meeting, Society of Magnetic Resonance, Nice, France, 1995. p. 1144.
50. Not invented here. From Wikipedia, the free encyclopedia. Available at: http://en.wikipedia.org/wiki/Not-Invented-Here; Internet; accessed May 27, 2005.
51. Stillman AE, Wilke N, Jerosch-Herold M. Myocardial viability. Radiol Clin North Am. 1999;37:361-378.
52. Saeed M, Bremerich J, Wendland MF, et al. Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats. Radiology. 1999;213:247-257.
53. Lim TH, Choi SH. MRI of myocardial infarction. J Magn Reson Imaging. 1999;10:686-693.
54. Wendland MF, Saeed M, Lund G, et al. Contrast-enhanced MRI for quantification of myocardial viability. J Magn Reson Imaging. 1999;10: 694-702.
55. Choi SI, Choi SH, Kim ST, et al. Irreversibly damaged myocardium at MR imaging with a necrotic tissue-specific contrast agent in a cat model. Radiology. 2000;215:863-868.
56. Jeong AK, Choi SI, Kim DH, et al. Evaluation by contrast-enhanced MR imaging of the lateral border zone in reperfused myocardial infarction in a cat model. Korean-J-Radiol. 2002;2:21-7.
57. Lund GK, Higgins CB, Wendland MF, et al. Assessment of Nicorandil therapy in ischemic myocardial injury by using contrast-enhanced and functional MR imaging. Radiology. 2001;221:676-682.
58. Manrique A, Marie PY. The best of cardiac imaging 2002. Arch Mal Coeur Vaiss. 2003;96:73-85.
59. Choi SH, Lee SS, Choi SH, et al. Occlusive myocardial infarction: investigation of bis-Gadolinium mesoporphyrins-enhanced T1-weighted MR imaging in a cat model. Radiology. 2001;220:436-440.
60. Barkhausen J, Ebert W, Debatin JF, et al. Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol. 2002;39:1392-1398.
61. Ni Y, Chen F, Dymarkowski S, et al. Proper handling of research with invalid conclusion [Letter-to-Editor]. Radiology. 2003;229:608-610.
62. Schalla S, Wendland MF, Higgins CB, et al. Accentuation of high susceptibility of hypertrophied myocardium to ischemia: complementary assessment of gadophrin-enhancement and left ventricular function with MRI. Magn Reson Med. 2004;51:552-558.
63. Ni Y, Miao Y, Bosmans H, et al. Evaluation of interventional liver tumor ablation with Gd-mesoporphyrin enhanced magnetic resonance imaging (abs). Radiology. 1997;205:319.
64. Ni Y, Miao Y, Bosmans H, Yu J, et al. Evaluation of interstitial liver tumor ablation with gadophrin-2 enhanced MRI (abs). Eur Radiol. 1999;9(Suppl 1):1220.
65. Metz S, Daldrup-Link H, Richter T, et al. Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent gadophrin-3. Acad Radiol. 2003;10:484-490.
66. Krombach GA, Higgins CB, Gunther RW, et al. MR contrast media for cardiovascular imaging [in German]. Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr. 2002;174:819-829.
67. Daldrup-Link HE, Rudelius M, Metz S, et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging. 2004;31:1312-1321.
68. th Annual Scientific Meeting for ISMRM. 1999;1:346.
69. Marchal G, Verbruggen A, Ni Y, et al. Non-porphyrin compounds for use as a diagnosticum and/or pharmaceutical. International Patent Application PTC/BE99/00104; Filing date: August 5, 1999.
70. Cresens E, Ni Y, Adriaens P, et al. Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them. International Patent Application PCT/BE01/00192, Filing date November 7, 2001.
71. Jorgensen M. Quantitative determination of pamoic acid in dog and rat serum by automated ion-pair solid-phase extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998;716:315-323.
72. Shaaban M, Maskey RP, Wagner-Dobler I, et al. Pharacine, a natural p-cyclophane and other indole derivatives from Cytophaga sp. strain AM13. 1. J Natl Prod. 2002;65:1660-1663.
73. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect. 2004;112:1058-1062.
74. Ni Y, Mulier S, Miao Y, Michel L, et al. A review of the general aspects of radiofrequency ablation [invited review]. Abdom Imaging 2005;30: (in press). Published online: 23 March 2005 (10.1007/s00261-004-0253-9).
75. Ni Y, Chen F, Marchal G. Differentiation of residual tumor from benign periablational tissues after radiofrequency ablation: the role of MRI contrast agents [Letter to the Editor]. Radiology. 2005, in press.
76. Goldberg SN. Can we differentiate residual untreated tumor from tissue responses to heat following thermal tumor ablation? Radiology. 2005; 234:317-318.
77. Kim TJ, Moon WK, Cha JH, et al. VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology. 2005;234:423-430.
78. Ni Y, Østensen J, Zhang H, et al. The potential role of necrosis avid contrast agents in therapeutic evaluation of radiofrequency tumor ablation: an experimental study in rat model of liver metastasis (abs). MAGMA. 2002;15(Suppl 1):17.
79. Ni Y, Østensen J, Cresens E, et al. Multipurpose applications of necrosis avid contrast agent for MRI detection of liver metastasis and therapeutic evaluation of radiofrequency ablation: an experimental study in rats [abstract]. Radiology. 2002;225(P):392.
80. Taupitz M, Wagner S, Schnorr J, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol. 2004;39:394-405.
81. Schnorr J, Wagner S, Abramjuk C, et al. Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest Radiol. 2004;39:546-553.
82. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
83. Spokojny AM, Serur JR, Skillman J, et al. Uptake of hematoporphyrin derivative by atheromatous plaques: studies in human in vitro and rabbit in vivo. J Am Coll Cardiol. 1986;8:1387-1392.
84. Vever-Bizet C, L'Epine Y, Delettre E, et al. Photofrin II uptake by atheroma in atherosclerotic rabbits. Fluorescence and high performance liquid chromatographic analysis on post-mortem aorta. Photochem Photobiol. 1989;49:731-737.
85. Woodburn KW, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg. 1996; 14:343-348.
86. Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004;39:56-63.
87. Corot C, Petry KG, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol. 2004;39:619-625.
88. Hofmann B, Bogdanov A, Marecos E, et al. Mechanism of gadophrin-2 accumulation in tumor necrosis. J Magn Reson Imaging. 1999;9:336-341.
89. Ni Y, Adzamli K, Miao Y, Cresens et al. MRI Contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction. Invest Radiol. 2001;36:97-103.
90. Lauffer RB. Targeted relaxation enhancement agents for MRI. Magn Reson Med. 1991;22:339-342.
91. Ni Y, Huyghe D, Chen F, et al. Research on necrosis avid contrast agents: further expansion of scope. Acad Radiol, in press.
92. Parac-Vogt TN, Kimpe K, Laurent S, et al. Synthesis, characterization and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centra with albumin binding affinity. Chemistry. 2005;11:3077-3086.
93. Hamer PW, McGeachie JM, Davies MJ, et al. Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat. 2002;200:69-79.
94. Ni Y, Bormans G, Marchal G, Verbruggen A. Tissue infarction and necrosis specific compounds (of hypericin derivatives). PCT/BE2004/ 000107 Patent application. Priority date July 25, 2003.
95. Fonge HA, Bormans G, Ni Y, et al. Evaluation of mono-1-123-Hypericin as necrosis avid tracer agent. Eur J Nucl Med Mol 1. 2004;31(Suppl 2):S381.
96. Orlandi C, Crane PD, Edwards DS, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med. 1991;32:263-268.
97. Okada DR, Johnson G III, Liu ZL, et al. Early detection of infarct in reperfused canine myocardium using 99mTc-Glucarate. J Nucl Med. 2004;45:655-664.
98. Mikawa M, Kato H, Okumura M, et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem. 2001;12:510-514.